What amount sold does Boston Therapeutics, Inc. report in Form D filings?

The latest linked filings report $12.5M sold across 4 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Boston Therapeutics, Inc.'s most recent SEC filing?

Boston Therapeutics, Inc.'s most recent Form D filing was on 2021-07-09.

How many investors does Boston Therapeutics, Inc. have?

The most recent Form D filing lists 5 investor(s).

What type of securities does Boston Therapeutics, Inc. offer?

Boston Therapeutics, Inc.'s SEC Form D filings indicate debt offerings.

Boston Therapeutics, Inc.

CIK: 0001473579·Biotechnology·LAWRENCE, MA·Corporation

Reported Sold

$12,542,778

Total Filings

Identified Offerings

Last Filed

Jul 9, 2021

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Jul 9, 2021Form D — New notice

Reported sold: $8,434,778 · Target: $8,434,778

Rule 506(b)·5 investors

Sep 20, 2016Form D/A — Amendment

Reported sold: $1,600,000 · Target: $2,000,000

Rule 506(b)·28 investors

Changed: Reported amount sold, Reported investors, Sales commissions

Aug 25, 2016Form D — New notice

Reported sold: $1,322,500 · Target: $2,000,000

Rule 506(b)·25 investors

Aug 7, 2013Form D — New notice

Reported sold: $2,000,000 · Target: $8,000,000

Rule 506·1 investor

Jul 5, 2011Form D — New notice

Reported sold: $508,000 · Target: $508,000

Rule 506·88 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

$220,000

Amendment Rate

20%

Latest reported sold across 4 identified offerings

$12,542,778

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Rom Eliaz

Related Person

Appears on 3 filings

Dale H. Conaway

Related Person

Appears on 2 filings

Conroy Chi-Heng Cheng

Related Person

Appears on 2 filings

Carl Lueders

Related Person

Appears on 2 filings

Henry Esber

Related Person

Appears on 2 filings

Carl W. Rausch

Related Person

Appears on 1 filing

Dale Conway

Related Person

Appears on 1 filing

Kenneth Tassey, Jr.

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Jul 9, 2021	New	$8,434,778	$8,434,778	5
Sep 20, 2016	Amendment	$2,000,000	$1,600,000	28
Aug 25, 2016	New	$2,000,000	$1,322,500	25
Aug 7, 2013	New	$8,000,000	$2,000,000	1
Jul 5, 2011	New	$508,000	$508,000	88

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Unravel Biosciences, Inc.

Biotechnology

Offering target: $4,500,000

Filed Aug 24, 2026